View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 10, 2019updated 12 Jul 2022 1:06pm

ICON introduces new platform for potential trial participants

Ireland-based ICON has launched a new patient engagement platform to support people interested in participating in clinical trials by offering study specific information.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The platform also provides patients with connectivity to the nearest trial site. In addition, it improves visibility of potential trial subjects for sponsors and sites.

Outreach programmes for patient enrolment will be developed by combining standard approaches with digital channels and patient advocacy collaborations. These programmes are intended to attract patients to a study branded website that will be hosted on the platform.

The platform comes with a user-friendly interface to guide patients to new and ongoing trials in their particular indication. It features a pre-qualification questionnaire to help determine the suitability of the study.

ICON Site & Patient Solutions senior vice-president EB McLindon said: “Access to patients continues to be the biggest challenge for sponsors, impacting speed to market and overall drug development costs.

“We have used our understanding of patients gained through managing thousands of trials to develop this patient engagement platform and ease the burden on sites and patients. This will increase the predictability and speed of patient recruitment.”

The company added that the new platform enables at-home discussion of the possibility of trial participation as a clinical care option at home.

When a patient decides to register interest, the platform provides an option to select their nearest investigative site. This in turn enhances access to potential patients for sponsors.

Furthermore, site staff will be able to view the number of completed pre-qualification questionnaires for monitoring and reporting on progress to sponsors.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena